Design of the SARTAN-AD trial: a randomized open label proof of concept study of Telmisartan vs Perindopril in hypertensive Alzheimer’s Disease patients

Please join us …

When: Tuesday, April 11, 2017, 12–1 p.m.

Where: ICES, G-Wing, Conference Centre (Sunnybrook Health Sciences Centre)

Who: Sandra Black, O.C., O.Ont., MD, FRCP(C), FRSC, FAAN, FAHA, FANA; Brill Chair in Neurology, Department of Medicine, Sunnybrook Health Sciences Centre & University of Toronto;
Site Leader, Canadian Partnership for Stroke Recovery;
Executive Director, Toronto Dementia Research Alliance;
Hurvitz Brain Sciences Research Program Director, Sunnybrook Research Institute.

Topic: Design of the SARTAN-AD trial: a randomized open label proof of concept study of Telmisartan vs Perindopril in hypertensive Alzheimer’s disease patients

Learning objectives

To appreciate the role of clinical trials to repurposing existing medications for potential treatment of Alzheimer’s Disease
To understand preclinical and clinical evidence for the potential utility of angiotensin receptor blockers (ARBs), and angiotensin-converting enzyme inhibitors (ACEIs) as pharmacotherapy for Alzheimer’s Disease
To understand preclinical and clinical evidence for the potential utility of angiotensin receptor blockers (ARBs), and angiotensin-converting enzyme inhibitors (ACEIs) as pharmacotherapy for Alzheimer’s Disease.